Journal of Gynecologic Oncology最新文献

{"title":"The past, present, and future of FIGO staging of endometrial cancer.","authors":"Xiaoyan Zhao, Fujing Sun, Nankun Leng, Xin Zhang, Yanmei Zhu","doi":"10.3802/jgo.2025.36.e105","DOIUrl":"10.3802/jgo.2025.36.e105","url":null,"abstract":"<p><p>The International Federation of Gynecology and Obstetrics (FIGO) staging of endometrial cancer (EC) is regarded as a crucial tool for guiding treatment, evaluating prognosis, and advancing clinical research. It is a concept of shared importance among gynecologic oncologists, pathologists, and patients with EC. In June 2023, the International Federation of Gynecology and Obstetrics released a new staging system for EC. This review aims to discuss comprehensively the developmental trajectory of FIGO staging for EC, focusing on the differences between the 2023 FIGO and earlier staging systems, and delineating the advantages and disadvantages of incorporating various pathological factors and molecular subtypes into staging. The article emphasizes the progress made with the updated 2023 FIGO version in improving prognostic prediction accuracy for patients with EC. However, as the staging categories expand, their complexity becomes increasingly apparent, potentially impacting health care professionals' accurate understanding and application of staging. Moreover, unresolved issues persist regarding histological types and grading, lymphovascular space invasion, and molecular subtypes, as well as distinguishing between low-grade endometrioid carcinomas confined to the uterus and ovaries, which may affect the personalized management of patients with EC. In the future, these issues still require extensive clinical research and specific data for validation or confirmation, presenting a challenge shared by gynecologic oncologists and pathologists.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e105"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive deficit identified via pre-operative patient reported outcome measures is a predictor for post-operative health care utilization in gynecologic oncology patients.","authors":"Aashna Saini, John Endel Orav, Rachel Clark Sisodia, Lauren Philp","doi":"10.3802/jgo.2025.36.e60","DOIUrl":"10.3802/jgo.2025.36.e60","url":null,"abstract":"<p><strong>Objective: </strong>To determine if preoperative Patient-Reported Outcome Measures (PROMs) can be used to predict post-operative health care utilization in gynecology oncology patients.</p><p><strong>Methods: </strong>A retrospective study was performed after Institutional Review Board approval. PROMs were collected pre-operatively from all patients undergoing surgery for gynecologic malignancy between 1/1/18 and 9/1/19 at a tertiary academic medical center. Patients received the EORTC QLQ-C30 and Patient-Reported Outcomes Measure Information System emotional and instrumental support questionnaires along with a disease specific PROM. Charts were reviewed to ascertain healthcare utilization (\"touches\") in the 90-day postoperative period defined as phone calls, emails or portal messages, office visits, emergency department (ED) encounters, and hospital admissions. Linear regression was used to identify PROMs associated with postoperative healthcare utilization.</p><p><strong>Results: </strong>Three hundred seventy-one patients were administered questionnaires of which 307 (82.7%) completed PROMs and were included for analysis. A significant association was noted between adverse responses on many EORTC QLQ-C30 domains and increased postoperative healthcare utilization. Of all questions, \"difficulty remembering things\" was most strongly associated with both overall utilization (total touches p=0.01) and utilization in multiple domains. After forward selection against other significant PROMs, as difficulty with memory increased, both overall healthcare utilization (adjusted regression coefficient 1.9, p=0.01) and ED encounters increased (adjusted regression coefficient 0.10, p=0.01).</p><p><strong>Conclusion: </strong>Patients who report cognitive concerns are significantly more likely to have higher healthcare utilization postoperatively. Attention to this preoperatively could help identify patients at higher risk and further studies should determine if additional support around surgery can mitigate this risk.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e60"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226320/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of para-aortic node metastasis in endometrial cancer: Japanese Gynecologic Oncology Group Study JGOG2043 post hoc analysis.","authors":"Yosuke Konno, Michinori Mayama, Kazuhiro Takehara, Yoshihito Yokoyama, Jiro Suzuki, Nobuyuki Susumu, Kenichi Harano, Satoshi Nakagawa, Toru Nakanishi, Wataru Yamagami, Kosuke Yoshihara, Hiroyuki Nomura, Aikou Okamoto, Daisuke Aoki, Hidemichi Watari","doi":"10.3802/jgo.2025.36.e57","DOIUrl":"10.3802/jgo.2025.36.e57","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess the prognostic significance of para-aortic lymphadenectomy (PALX) and para-aortic lymph node metastasis in endometrial cancer (EC) patients at risk of post-operative recurrence.</p><p><strong>Methods: </strong>Japanese Gynecologic Oncology Group (JGOG) 2043 was a randomized controlled trial assessing the efficacy of adjuvant chemotherapy in EC patients at risk for post-operative recurrence. A retrospective analysis included patients who underwent pelvic lymphadenectomy (PLX) alone or both PLX and PALX in JGOG2043. Data on positive lymph nodes and other clinicopathological risk factors were collected.</p><p><strong>Results: </strong>PLX and PALX were performed on 402 patients, while PLX alone was conducted on 250 patients. Evaluating the effect of PALX on survival was challenging through a comparison of the outcomes of the 2 cohorts since PALX was predominantly administered to higher-risk patients. Patients with 2 or more metastases in para-aortic nodes exhibited significantly poorer overall survival than those with no or 1 metastasis, respectively (p<0.001, p=0.031). Multivariate analysis revealed that 2 or more metastases in para-aortic nodes is independent risk factors for disease-free survival (hazard ratio [HR]=1.72; 95% confidence interval [CI]=1.10-2.72; p=0.019) and are marginally significant for overall survival (HR=1.58; 95% CI=0.92-2.72; p=0.096) compared to no or a single metastasis.</p><p><strong>Conclusion: </strong>The clinical relevance of PALX was challenging to evaluate in the JGOG2043 cohort; however, the presence of 2 or more para-aortic node metastases was identified as an independent unfavorable prognostic factor in EC patients at risk of recurrence.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e57"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognosis impact of NACT-IDS and PDS in advanced ovarian cancer: a systematic review and meta-analysis.","authors":"Qiuxian Xie, Min Cui","doi":"10.3802/jgo.2025.36.e61","DOIUrl":"10.3802/jgo.2025.36.e61","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to explore the prognostic implications of neoadjuvant chemotherapy and interval debulking surgery (NACT-IDS) compared to primary debulking surgery (PDS) in patients diagnosed with advanced ovarian cancer by meta-analysis.</p><p><strong>Methods: </strong>The search was conducted across PubMed, Web of Science, Cochrane, Wanfang Data, China National Knowledge Infrastructure, and the Chinese BioMedical Literature Database to identify pertinent studies examining the prognostic implications of NACT-IDS versus PDS in patients with advanced ovarian cancer.</p><p><strong>Results: </strong>As of September 11, 2023, a total of 29 articles were ultimately included, encompassing 12,916 patients with advanced ovarian cancer in this meta-analysis. NACT-IDS groups exhibited a higher satisfactory tumor reduction rate (odds ratio [OR]=2.06; 95% confidence interval [CI]=1.53 to 2.76; p<0.001). NACT-IDS effectively reduced the risk of adverse cardiac events (OR=0.36; 95% CI=0.17 to 0.80; p=0.012), surgical site infections (OR=0.42; 95% CI=0.29 to 0.60; p<0.001), and embolic complications (OR=0.43; 95% CI=0.24 to 0.75; p=0.003) in patients with advanced ovarian cancer. Compared to NACT-IDS therapy for International Federation of Gynecology and Obstetrics (FIGO) III-IV ovarian cancer patients (OR=1.66; 95% CI=1.24 to 2.23; p=0.009), NACT-IDS groups exhibited a higher satisfactory tumor reduction rate for FIGO IIIC-IV (OR=2.35; 95% CI=1.50 to 3.70; p<0.001).</p><p><strong>Conclusion: </strong>NACT-IDS effectively enhances the satisfactory tumor reduction rate, especially for patients with stage IIIC and IV, and decreases postoperative complications among patients with advanced ovarian cancer.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e61"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial.","authors":"Kenichi Harano, Roldano Fossati, Beatriz Pardo, Francesca Galli, Emma Hudson, Yoland Antill, Chulmin Lee, Manuela Rabaglio, Florian Heitz, Vassiliki Kolovetsiou-Kreiner, Chyong-Huey Lai, Elena Biagioli, Luis Manso, Shin Nishio, Karen Allan, Yeh Chen Lee, Sara Uggeri, Andres Redondo, Satoshi Nakagawa, Eunice Au, Janine Lombard, Angiolo Gadducci, Kazuhiro Takehara, Edi Editta Baldini, Innocenza Palaia, Claudia Casanova, Antonio Ardizzoia, Alessandra Bologna, Maria-Pilar Barretina-Ginesta, Nicoletta Colombo","doi":"10.3802/jgo.2025.36.e117","DOIUrl":"10.3802/jgo.2025.36.e117","url":null,"abstract":"<p><strong>Objective: </strong>This post-hoc analysis of the AtTEnd trial explored differences in the prognostic characteristics and in the efficacy of atezolizumab between Asians and non-Asians.</p><p><strong>Methods: </strong>The role of Asian race was evaluated on progression-free survival (PFS) using Cox-models and on time to appearance of new lesions using Fine and Gray models.</p><p><strong>Results: </strong>From October 2018 to February 2022, 549 patients were randomized, of whom, 20.4% were Asian. Asians showed a better prognostic profile in terms of age, body mass index, Eastern Cooperative Oncology Group performance status, disease status and previous treatments. The prognostic impact of Asian race on PFS was confirmed in the placebo arm (adjusted hazard ratio [HR]=0.41; 95% confidence interval [CI]=0.24-0.70). In proficient mismatch repair (pMMR) tumors, the HRs for PFS comparing atezolizumab versus placebo were 0.82 (95% CI=0.63-1.05) in non-Asians, and 1.42 (95% CI=0.80-2.50) in Asians. In the pMMR population randomized to atezolizumab, the subdistribution HRs comparing Asians to non-Asians were 0.68 (95% CI=0.43-1.09) for progression with new lesions and 1.21 (95% CI=0.73-2.03) for progression without new lesions. Asians showed a higher occurrence of severe adverse events in atezolizumab compared to placebo arm (Asians: 82.1% vs. 64.3%, p=0.036; non-Asian: 63.3% vs. 63.6%, p=0.949).</p><p><strong>Conclusion: </strong>Race seems to affect the safety of the addition of atezolizumab and, in pMMR tumors, also its efficacy. In the atezolizumab arm, Asian patients seem to have a lower cumulative incidence of new lesions when primary tumor regrowth was considered a competing risk, and a higher cumulative incidence of primary tumor regrowth when new lesions appearance was the competing risk.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT03603184.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":"36 4","pages":"e117"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differentiation of uterine fibroids and sarcomas by MRI and serum LDH levels: a multicenter study of the KAMOGAWA study.","authors":"Yukio Yamanishi, Yasushi Kotani, Aki Kido, Tomoyuki Otani, Yuki Himoto, Yasuhisa Kurata, Kosuke Murakami, Hisamitsu Takaya, Masahiro Sumitomo, Ikuko Emoto, Motonori Matsubara, Naoki Horikawa, Kana Akagi, Kentaro Ishida, Aya Takaori, Azusa Sakurai, Kaoru Abiko, Koji Yamanoi, Masaki Mandai, Noriomi Matsumura","doi":"10.3802/jgo.2025.36.e58","DOIUrl":"10.3802/jgo.2025.36.e58","url":null,"abstract":"<p><strong>Objective: </strong>In the differential diagnosis between uterine fibroids and uterine sarcomas, real-world magnetic resonance imaging (MRI) diagnostic information is scarce; furthermore, high diagnostic sensitivity is important in clinical practice. We previously developed a diagnostic algorithm to detect uterine sarcoma with high sensitivity using simple MRI images and serum lactate dehydrogenase (LDH) levels. In this multicenter study, we investigated the preoperative diagnosis of sarcoma in the real world and further validated the usefulness of our diagnostic algorithm.</p><p><strong>Methods: </strong>Of 154 uterine sarcomas and 154 uterine fibroids treated at 15 centers between January 2006 and December 2020, 139 sarcomas (16 smooth muscle tumors of uncertain malignant potential) and 141 fibroids with diffusion-weighted imaging information were included in the analysis. The diagnostic algorithm was validated by 3 radiologists who were blinded to the clinical information and pathologic diagnoses and who read the MRIs.</p><p><strong>Results: </strong>The sensitivity/specificity of preoperative diagnosis was 77.7%/92.9% for the preoperative report; 92.1%/72.3% for algorithm A; and 82.0%/85.8% for algorithm B (McNemar's test p<0.05). Comparison of overall survival rates among 3 groups (Group 1: negative A, Group 2: positive A and negative B; Group 3: positive B) using algorithms A and B showed p=0.012. On multivariate analysis, stage, and serum LDH level were independent prognostic factors.</p><p><strong>Conclusion: </strong>MRI is useful for preoperative diagnosis of uterine sarcoma, and the sarcoma diagnostic algorithm presented in this study is an option for diagnosing sarcoma with greater sensitivity. This information should be shared with patients.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e58"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226314/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial.","authors":"Shin Nishio, Tadaaki Nishikawa, Masahiko Mori, Shoji Kamiura, Toshiyuki Sumi, Mayu Yunokawa, Yuichi Imai, Eiji Kondo, Kazuhiro Takehara, Hirokuni Takano, Wataru Kudaka, Nobuhiro Kado, Wataru Yamagami, Hidenori Kato, Koji Nishino, Tomoka Usami, Junzo Hamanishi, Masahiro Nii, Itsumi Takaya, Aikou Okamoto","doi":"10.3802/jgo.2025.36.e118","DOIUrl":"10.3802/jgo.2025.36.e118","url":null,"abstract":"<p><strong>Objective: </strong>DUO-E/GOG-3041/ENGOT-EN10 (NCT04269200) demonstrated statistically significant and clinically meaningful progression-free survival (PFS) improvement with durvalumab plus carboplatin/paclitaxel, followed by durvalumab with or without olaparib, vs. carboplatin/paclitaxel alone (intention-to-treat [ITT] population) in patients with newly diagnosed advanced or recurrent endometrial cancer. We evaluated efficacy and safety in the Japan subset of DUO-E.</p><p><strong>Methods: </strong>Patients with newly diagnosed International Federation of Gynecology and Obstetrics stage III/IV or recurrent endometrial cancer were randomized 1:1:1 to control arm (carboplatin/paclitaxel + durvalumab placebo [6 cycles] followed by durvalumab placebo + olaparib placebo), durvalumab arm (carboplatin/paclitaxel + durvalumab [1,120 mg every 3 weeks] [6 cycles] followed by durvalumab [1,500 mg every 4 weeks] + olaparib placebo), or durvalumab + olaparib arm (carboplatin/paclitaxel + durvalumab [6 cycles] followed by durvalumab + olaparib [300 mg twice a day]). Dual primary endpoints were investigator-assessed PFS for durvalumab and durvalumab + olaparib arms vs. control. This prespecified exploratory analysis evaluated PFS and safety in the Japan subset.</p><p><strong>Results: </strong>In the Japan subset (n=88) PFS favored durvalumab (hazard ratio=0.61, 95% confidence interval [CI]=0.32-1.12) and durvalumab + olaparib (0.44, 95% CI=0.22-0.85) vs. control; median PFS was 9.9 and 15.1 vs. 9.5 months, and the 18-month PFS rate was 37.0% and 42.1% vs. 22.2%, respectively. The safety profile in the Japan subset was generally consistent with the full safety analysis set and the established profiles of the individual agents.</p><p><strong>Conclusion: </strong>Efficacy and safety in the Japan subset were generally consistent with outcomes in the DUO-E ITT population. This Japanese subset analysis of DUO-E supports carboplatin/paclitaxel + durvalumab followed by durvalumab with or without olaparib as new treatment options in patients with advanced or recurrent endometrial cancer and is the first to report on these regimens in Japanese patients alone.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":"36 4","pages":"e118"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early prediction and risk stratification of ovarian cancer based on clinical data using machine learning approaches.","authors":"Ting Gui, Dongyan Cao, Jiaxin Yang, Zhenhao Wei, Jiatong Xie, Wei Wang, Yang Xiang, Peng Peng","doi":"10.3802/jgo.2025.36.e53","DOIUrl":"10.3802/jgo.2025.36.e53","url":null,"abstract":"<p><strong>Objective: </strong>Our study was aimed to construct a predictive model to advance ovarian cancer diagnosis by machine learning.</p><p><strong>Methods: </strong>A retrospective analysis of patients with pelvic/adnexal/ovarian mass was performed. Potential features related to ovarian cancer were obtained as many as possible. The optimal machine learning algorithm was selected among six candidates through 5-fold cross validation. Top 20 features having the most powerful predictive significance were ranked by Shapley Additive Interpretation (Shap) method. Clinical validation was further performed to confirm whether our model could advance diagnosis of ovarian cancer.</p><p><strong>Results: </strong>A total of 9,799 patients were collected. The inclusion criteria included age >18 years old, the first diagnosis being pelvic/adnexal/ovarian mass of undetermined significance, and pathological report indispensable. Four hundred and thirty-eight dimensional features were obtained after filtration. LightGBM showed the best performance with accuracy 88%. Among the top 20 features, 55% belonged to laboratory test report, 35% came from imaging examination report, and 10% were attributed to basic demographics and main symptom. Age, CA125, and risk of ovarian malignancy algorithm were the top three. Our predictive model performed stably in testing and clinical validation datasets, and was found to advance the diagnosis of ovarian cancer about 17 days before clinical pathological examination.</p><p><strong>Conclusion: </strong>LightGBM was the optimal algorithm for our predictive model with accuracy of 88%. Laboratory test and imaging examination played essential roles in diagnosing ovarian cancer. Our model could advance the diagnosis of ovarian cancer before clinical pathological examination.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e53"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"UPF1 inhibits cervical cancer cell migration and invasion by regulating nonsense-mediated decay of <i>BMP6</i> and lncRNA <i>WAKMAR2</i>.","authors":"Guligeina Abudourexiti, Jingjing Zhang, Guzhanuer Abuduxikuer","doi":"10.3802/jgo.2025.36.e127","DOIUrl":"10.3802/jgo.2025.36.e127","url":null,"abstract":"<p><strong>Objective: </strong>Up-frameshift protein 1 (UPF1) can contribute to the progression of a variety of cancers. Currently, there is limited research on UPF1 in cervical cancer, and further investigation is necessary to understand its regulatory mechanisms in cervical cancer.</p><p><strong>Methods: </strong>mRNA expression was detected by quantitative real-time polymerase chain reaction, while protein expression was quantified by western blotting assay. Cell function was assessed by cell counting kit-8 assay, Transwell assay and wound-healing assay. A xenograft mouse model assay was performed to analyze the effect of UPF1 silencing on tumor formation. Differentially expressed genes in cell samples were screened using the R Bioconductor package DESeq2. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analysis was performed to determine the functional categories of the differentially expressed genes.</p><p><strong>Results: </strong>UPF1 expression was downregulated in cervical cancer tissues and cells. Additionally, UPF1 silencing promoted invasion and migration of cervical cancer cells and tumor formation. There were a total of 188 upregulated genes in the SiHa cells after UPF1 silencing. Biological analysis showed that these upregulated genes were enriched in pathways related to regulation of cell proliferation, positive regulation of gene expression, cell adhesion, and Hippo signaling pathway. Additionally, UPF1 depletion promoted SiHa cell proliferation, invasion and migration, whereas the effects were attenuated after silencing of bone morphogenetic protein 6 (<i>BMP6</i>) or long non-coding RNA (lncRNA) <i>WAKMAR2</i>.</p><p><strong>Conclusion: </strong>UPF1 inhibited cervical cancer cell migration and invasion through the regulation of nonsense-mediated decay of <i>BMP6</i> and lncRNA <i>WAKMAR2</i>.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncogenic pathway landscape of ovarian cancer and correlation with clinical prognosis.","authors":"Young-Jae Lee, Na-Eun Kim, Jung-Hyun Bae, Chang-Ohk Sung, Shin-Wha Lee, Dae-Yeon Kim, Yong-Man Kim","doi":"10.3802/jgo.2025.36.e128","DOIUrl":"https://doi.org/10.3802/jgo.2025.36.e128","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to identify the main oncogenic pathway by histological type of ovarian cancer based on Next-generation sequencing (NGS) test and to determine the correlation with clinical prognosis.</p><p><strong>Methods: </strong>We conducted a retrospective review of 420 patients with ovarian cancer who underwent NGS testing at Asan Medical Center from June 1, 2017, to May 31, 2021. Identified mutations were categorized into seven oncogenic pathways that are most frequently associated with ovarian cancer.</p><p><strong>Results: </strong>The average number of oncogenic pathways involved in each cancer patient was 1.76 (range, 0-6). TP53 mutation was the primary oncogenic pathway in patients with high-grade serous carcinoma (HGSC) (92.8%) and carcinosarcoma (87.5%). MAP kinase signaling was the primary oncogenic pathway in low-grade serous carcinoma (58.3%) and mucinous carcinoma (54.5%). The involvement of more diverse oncogenic pathways has been identified in patients with endometrioid carcinoma and clear cell carcinoma and PI3K-AKT-mTOR signaling and SWI/SNF family pathways were the most common in both groups. The involvement of the DNA damage response pathway showed an association with better progression free survival (PFS), but not with overall survival (OS) in patients with HGSC. On the other hand, the involvement of the RTK signaling family pathway showed an association with better OS despite no association with PFS in patients with HGSC.</p><p><strong>Conclusion: </strong>The clinical prognosis may be improved by implementing targeted treatment tailored to the patient's genetic profile through NGS. Additional research is needed to determine whether the involvement of the RTK signaling family pathway is indeed associated with better OS and to identify the underlying reasons for this association.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}